「the 20」の検索結果
145件：46～50件目を表示
-
Data And Statistics | About Senju | SENJU Pharmaceutical
6% 2.2 4.7% 2.6 5.5% 2.8 5.7% Overseas Business 5.1 12.5% 6.4 15.8% 8.1 17.5% 9.9 20.3% 10.9 22.4% Others 0.5 1.2% 2.0 5.0% 2.0 4.4% 2.2 4.7% 1.4 2.9% ＊A new accounting standard for revenue recognitio...
https://www.senju.co.jp/english/about/sales.html -
千寿製薬株式会社
NEWS & RELEASE April 6, 2026 Launch of “Avarept® Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition（PDF） December 22, 2025 Obtained manufacturing a...
http://www.senju.co.jp/english/ -
学会发表 | 研究与开发 | 千寿制药株式会社
o-Controlled Phase 3 Pivotal Study – Yuichi Hori, MD, PhD; Tomoyuki Wada, PhD; Kazunori Omatsu, BSc the 59th Congress of the European Societies of Toxicology 開催日：2025年9月14日～2025年9月17日 開催地：Athens, GREE...
http://www.senju.co.jp/chinese/rd/society/ -
R&D Pipeline | Research & Development | SENJU Pharmaceutica
70GlaucomaP3（Japan） SJP-0154Dry eyeP2（Japan） SJP-0049Allergic ConjunctivitisP2（Japan） As of January 2026
https://www.senju.co.jp/english/rd/pipeline.html -
发表论文 | 研究与开发 | 千寿制药株式会社
zed, Double-Masked, Dose-Finding Study Yuichi Hori1, Tomoyuki Wada2, Kazunori Omatsu2, on behalf of the SJP-0132 clinical study investigators 1: Department of Ophthalmology, Toho University Faculty of...
http://www.senju.co.jp/chinese/rd/thesis/